Bachem, a Swiss Speciality cGMP-Manufacturer: History and Future Prospects

Abstract

This article summarizes the development of the Bachem Group and the ongoing commitment regarding its production facilities in Switzerland. Bachem's core business, the manufacture of peptides from lab scale to market quantities, is explained using showcases to detail the high level of know-how needed to successfully prepare very large biomolecules. Based on these examples, the complexity regarding production processes and allocation of manufacturing sites are elucidated.

Bachem – Insights into Peptide Chemistry Achievements by the World's Leading Independent Manufacturer of Peptides

“…LHRH (GnRH, gonadorelin) and LHRH agonists such as goserelin or leuprolide are synthesized by solution-phase methods, which also enabled us to obtain longer peptide APIs such as somatostatin or calcitonin on large scale. [4] The synthesis of somatostatin represents a typical example for this methodology (Scheme 1).…”

Development of influenza virosome-based synthetic malaria vaccines

“…Although no examples of commercially available synthetic peptide-based vaccines exist at present, this type of vaccine has intrinsic advantages that will be realized in future. Synthetic peptides are easy to manufacture and the up-scaling under current good manufacturing practices has been established [2] . Using this approach, humoral immune responses can be focused to generate a preferred repertoire of antibodies that target defined epitopes known for their ability to afford protection.…”